Associated Papers
RBM10 Mutation as a Potential Negative Prognostic/Predictive Biomarker to Therapy in Non-Small-Cell Lung Cancer.
Reyes A et al.
Clinical Lung Cancer, 2024
The Mutational, Prognostic, and Therapeutic Landscape of Neuroendocrine Neoplasms.
Liu M et al.
The Oncologist, 2023
37086484 (PubMed )
Supplement: oyad093_suppl_supplementary_table_2.xlsx › Sheet1
Mosaicism in Tumor Suppressor Gene Syndromes: Prevalence, Diagnostic Strategies, and Transmission Risk.
Chen JL et al.
Annual Review of Genomics and Human Genetics, 2022
36044908 (PubMed )
Supplement: gg23-giannikou_suptable1.xlsx › TP53
Analytic validation and real-time clinical application of an amplicon-based targeted gene panel for advanced cancer.
Wing MR et al.
Oncotarget, 2017
29100271 (PubMed )
Supplement: oncotarget-08-75822-s008.xlsx › S7._167_patients
Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia.
Malcikova J et al.
Leukemia, 2015
25287991 (PubMed )
Supplement: leu2014297x1.pdf
Select a paper to view details